DBV Technologies Stock Falls 17.5% in One Month and Remains Under Pressure
The Châtillon biotech is recovering somewhat on Monday, posting a modest rebound in a nearly stable SBF 120. The stock nonetheless remains anchored below its three moving averages, in a context of structural selling pressure confirmed by rising short positions.
A Limited Rebound That Does Not Correct the Underlying Downtrend Over One Month
DBV Technologies gains 1.38% to €2.05 during the session, failing to erase the pressure accumulating over several weeks. Over one month, the stock falls another 17.27%, and over three months the decline reaches 28.67%. The price remains below the 20-day moving average at €2.21 (gap of 7.24%) and even further below the 50-day moving average at €2.35, which illustrates the extent of ground to be covered to return to a bullish configuration.
The RSI at 36, without signaling extreme oversold conditions, reflects persistent selling momentum that has not yet found its point of exhaustion. The €2.00 support remains the immediate technical reference, while the €2.57 resistance provides the measure of the rebound required to ease the squeeze.
Short Positions at 4.2% of Capital Increasing, as BLA Decision Remains Awaited from the FDA
According to reported disclosures, four funds cumulatively hold 4.21% of DBV Technologies capital in net short positions, up 0.82 percentage points over thirty days (compared to 3.39% one month ago). This level, above 4%, indicates real institutional downward pressure, even though the pace of increase does not suggest a sharp acceleration. These positions may reflect risk hedging as much as a directional bet, and warrant continued monitoring.
Against this backdrop, when first-half 2026 results were published on July 16, 2026, the company indicated that submission of the BLA dossier to the FDA was anticipated for the third quarter of 2026, with cash reserves covering needs through the third quarter of 2027. The realization of this regulatory milestone remains the reference point followed by market participants in assessing the stock's trajectory.
